Lupin launches Posaconazole delayed-release tablets; share dips 2%

Posaconazole had estimated annual sales of USD 186 million in the US

Buy Lupin; target of Rs 1350: Sharekhan

Sharekhan is bullish on Lupin has recommended buy rating on the stock with a target price of Rs 1350 in its research report dated January 29, 2021.

Buy Lupin; target of Rs 1287: Prabhudas Lilladher

Prabhudas Lilladher is bullish on Lupin has recommended buy rating on the stock with a target price of Rs 1287 in its research report dated January 29, 2021.

Buy Lupin; target of Rs 1165: ICICI Direct

ICICI Direct is bullish on Lupin has recommended buy rating on the stock with a target price of Rs 1165 in its research report dated January 29, 2021.

Buy Lupin; target of Rs 1180: Motilal Oswal

Motilal Oswal is bullish on Lupin has recommended buy rating on the stock with a target price of Rs 1180 in its research report dated January 30, 2021.

Lupin: New launches and market share gains are likely to override pricing erosion

New launches in the US, particularly in the inhalation category, and an improving market share are expected to help ride over structural pricing erosion in the near term for Lupin

Buy Lupin; target of Rs 1350: Sharekhan

Sharekhan is bullish on Lupin has recommended buy rating on the stock with a target price of Rs 1350 in its research report dated January 25, 2021.

Lupin Standalone December 2020 Net Sales at Rs 2,802.47 crore, up 3.19% Y-o-Y

Lupin Consolidated December 2020 Net Sales at Rs 4,017.36 crore, up 6.58% Y-o-Y

Lupin share price gains 2% on USFDA approval

The share touched its 52-week high Rs 1,121.85 and 52-week low Rs 505.00 on 18 September, 2020 and 13 March, 2020, respectively.

Lupin gets USFDA nod to market generic Sevelamer Carbonate tablets

The product is a generic version of Genzyme Corporation's Renvela tablets in the same strength, Lupin added.

Netflix's 'Lupin' marks rise of international TV content

The emergence of international platforms, mainly Netflix but also more recently Amazon and Disney+, has played a leading role in driving this appetite for content.

Lupin review: Netflix starts the year with a fabulous new show about a gentleman thief

Netflix creates Lupin magic in the smile of Omar Sy, and I think no one better could have been cast. The lone wolf of the comic book and anime is shown to be a dad here with the delightful Ludvine Sagnier playing his ex-wife.

Lupin gets USFDA nod for generic diabetes drug

The product will be manufactured at Lupin’s Nagpur-based manufacturing facility.

Lupin launches Mycophenolate Mofetil tablets in US

The newly launched product is the generic equivalent of CellCept tablets of Roche Palo Alto LLC.

Lupin shares rise 3% on USFDA nod

The share touched its 52-week high of Rs 1,121.85 and its 52-week low of Rs 505.00 on 18 September 2020 and 13 March 2020, respectively.

Buy Lupin; target of Rs 1212: Prabhudas Lilladher

Prabhudas Lilladher is bullish on Lupin has recommended buy rating on the stock with a target price of Rs 1212 in its research report dated November 06, 2020.

Buy Lupin; target of Rs 1120: HDFC Securities

HDFC Securities is bullish on Lupin has recommended buy rating on the stock with a target price of Rs 1120 in its research report dated November 06, 2020.

USFDA issues 13 observations after inspection of Lupin arm's Somerset facility

Lupin said it does not believe that this will have an impact on disruption of supplies or the existing revenues from operations of this facility.

Cipla: Covid opportunity and traction for Albuterol strong positives; accumulate

Cipla continues to be a significant pharma play during the pandemic because of its strong respiratory and a growing Covid portfolio

Cipla asks its IT team to be on alert after cyber attacks on major pharma firms

Cipla CFO Kedar Upadhye has asked his IT team to be as paranoid as possible and take the help of experts, and continue to track some hostile activities like conversations on the dark web, and multiple other things that one can do

Hold Lupin; target of Rs 985: ICICI Direct

ICICI Direct recommended hold rating on Lupin with a target price of Rs 985 in its research report dated November 06, 2020.

Business Insight | After Dr Reddy’s, Lupin reports cybersecurity attack

Just before the incident, Lupin had announced its September quarter results and Dr Reddy's had received approval for clinical trials of Russia’s Sputnik V vaccine

Lupin: Covid opportunity strengthens US business

The possibility of positive developments on the product pipeline front and restructuring initiatives can accelerate earnings growth for Lupin

Lupin expects 18.5% EBITDA margins in the second half of FY21 led by rebound of US, India businesses

Lupin said in order to achieve 18.5 percent EBITDA, it would also keep its expenses tight by restricting employee costs at 18 percent of sales